ReviewHuman vaccines2011
Advances and challenges towards a vaccine against Chagas disease.
Review in Human vaccines, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed.
- Immunization with the Tc85-Derived Peptide Displayed on Virus-like Particles Confers Protection againstACS omega · 2026Article
- The patent landscape of Chagas disease vaccines indicates major underinvestment in an emerging global health threat.Nature biotechnology · 2025Article
- Fighting Strategies Against Chagas' Disease: A Review.Pathogens (Basel, Switzerland) · 2025Review
- Review
- Chagas Disease: A Silent Threat for Dogs and Humans.International journal of molecular sciences · 2024Review
- Memory-like NK Cells Are a Critical Component of Vaccine-Induced Immunity to Trypanosoma cruzi Infection.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- New insights intoFrontiers in immunology · 2024Review
- Nanotechnology-Based Strategies in Parasitic Disease Management: From Prevention to Diagnosis and Treatment.ACS omega · 2023Review
- Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease.Pharmaceutics · 2022Article
- Why do we still have not a vaccine against Chagas disease?Memorias do Instituto Oswaldo Cruz · 2022Review
- α-Gal immunization positively impacts Trypanosoma cruzi colonization of heart tissue in a mouse model.PLoS neglected tropical diseases · 2021Article
- Library of Selenocyanate and Diselenide Derivatives as In Vivo Antichagasic Compounds TargetingPharmaceuticals (Basel, Switzerland) · 2021Article
- The Case for the Development of a Chagas Disease Vaccine: Why? How? When?Tropical medicine and infectious disease · 2021Review
- Nano-Medicines a Hope for Chagas Disease!Frontiers in molecular biosciences · 2021Review
- Extent of polymorphism and selection pressure on theEvolutionary applications · 2020Article
- Safety and immunogenicity of a recombinant vaccine against Trypanosoma cruzi in Rhesus macaques.Vaccine · 2020Article
- Article
- Immunity and vaccine development efforts against Trypanosoma cruzi.Acta tropica · 2019Review
- Effects of ghrelin supplementation on the acute phase of Chagas disease in rats.Parasites & vectors · 2019Article
- Inhibition of ER Stress by 2-Aminopurine Treatment Modulates Cardiomyopathy in a Murine Chronic Chagas Disease Model.Biomolecules & therapeutics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chagas disease is major public health problem, affecting nearly 10 million people, characterized by cardiac alterations leading to congestive heart failure and death of 20-40% of the patients infected with Trypanosoma cruzi, the protozoan parasite responsible for the disease. A vaccine would be key to improve disease control and we review here the recent advances and challenges of a T. cruzi vaccine. There is a growing consensus that a protective immune response requires the activation of a Th1 immune profile, with the stimulation of CD8 (+) T cells. Several vacines types, including recombinant proteins, DNA and viral vectors, as well as heterologous prime-boost combinations, have been found immunogenic and protective in mouse models, providing proof-of-concept data on the feasibility of a preventive or therapeutic vaccine to control a T. cruzi infection. However, several challenges such as better end-points, safety issues and trial design need to be addressed for further vaccine development to proceed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.